Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TARS

+ Watchlist+ Portfolio

Tarsus Pharmaceuticals, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$78.20
52-Week Range
$53.89 – $91.53
Market Cap
$3.74B
P/E (TTM)
—
EPS (TTM)
-15.86
Dividend Yield
0.00%
Advanced Metrics
Price/Book
36.00
PEG Ratio
—
Return on Equity
-319.84%
Return on Assets
-7.88%
Gross Margin
83.78%
Operating Margin
-9.61%
Profit Margin
-102.93%
Current Ratio
1.96
Debt/Equity
0.86
Total Debt
$89.43M
Free Cash Flow
$79.94M
Revenue Growth
63.90%
Earnings Growth
—
Enterprise Value
$3.52B

Market Snapshot

About

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying proven chemistry to address unmet needs in ophthalmic disease. The company's lead product candidate treats Demodex blepharitis, a disease caused by mite infestation of eyelids. Tarsus is developing novel therapeutic approaches for eye and skin conditions.